Erytech Pharma S.A. (ERYP) SEC Filing 6-K Foreign Issuer report for the period ending Monday, March 12, 2018

Erytech Pharma S.A.

CIK: 1624422 Ticker: ERYP

View differences made from one to another to evaluate Erytech Pharma S.A.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Erytech Pharma S.A..


Assess how Erytech Pharma S.A.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Erytech Pharma S.A.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Erytech Pharma S.A. provided additional information to their SEC Filing as exhibits

Ticker: ERYP
CIK: 1624422
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001193125-18-079452
Submitted to the SEC: Mon Mar 12 2018 5:18:56 PM EST
Accepted by the SEC: Mon Mar 12 2018
Period: Monday, March 12, 2018
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: